Controlled research has not shown RAD 140 lethargy, and the same goes for aggression, anxiety and insomnia, poor sleep despite enough opportunity to rest. The only human trial of RAD140 enrolled 22 women with advanced breast cancer, too few to rule such effects out. None appeared among its most frequent adverse events: raised liver enzymes, vomiting, dehydration and decreased appetite.
What is said about tiredness, mood and sleep comes mostly from accounts outside the trials, and there disturbed sleep is the complaint most often tied to RAD140, with anxiety, anger and tiredness mentioned less often. The rat studies do not fill the gap, because they measured whether neurons survived, not how the animals slept or behaved. So the trial is the only measured human record, and the RAD 140 mental effects this article follows, aggression, anxiety, disturbed sleep and tiredness, sit largely outside it.
Mood, sleep and energy effects against the evidence
Effect
Among the trial’s most frequent (>10%) adverse events
Measured in the rat brain studies
Where it is described
Tiredness
Not listed
Not measured; neuronal survival only
Descriptions outside the trials, less often than disturbed sleep
Disturbed sleep (insomnia, ‘radsomnia’)
Not listed
Not measured; neuronal survival only
Descriptions outside the trials, the effect most often linked with RAD140
Waking a few hours after falling asleep
Not listed
Not measured; neuronal survival only
Descriptions outside the trials
Anxiety
Not listed
Not measured; neuronal survival only
Descriptions outside the trials, less often than disturbed sleep
Aggression, irritability or anger
Not listed
Not measured; neuronal survival only
Descriptions outside the trials
Low mood
Not listed
Not measured; neuronal survival only
Descriptions outside the trials
Night sweats
Not listed
Not measured; neuronal survival only
Descriptions outside the trials, sometimes as part of wider sleep disturbance
Tinnitus
Not listed
Not measured; neuronal survival only
A single account outside the trials
Why would a compound tested against breast cancer touch sleep or mood at all? Testolone, as RAD140 is also called, is a selective androgen receptor modulator (SARM): it binds the androgen receptor, the protein inside cells through which testosterone and the other androgens act. Those hormones act on the brain as well as on muscle. That binding is the whole of the RAD 140 mechanism of action. The compound is orally active and reached clinical trials under the name vosilasarm.
Sleep, mood and energy are one strand of the wider record of RAD 140 side effects, which also covers liver injury, effects on the heart and changes in libido, and those strands belong to the parent article. Here the question is narrower: what the one human trial recorded about tiredness, mood and sleep, what is described outside it, and what the rat brain studies can and cannot add.
Mood, sleep and energy in the first human trial
The one human trial of RAD140 did not list tiredness, a change in mood or disturbed sleep among its most frequent treatment-emergent adverse events, the unwanted effects that begin or worsen once treatment starts. That silence has a plain cause. The trial was built to measure safety, tolerability, dosing, pharmacokinetics and activity against the tumour, and its published summary names no scale for mood or sleep. A complaint of tiredness could reach the record only if a patient reported it during treatment; nothing was scored against a baseline.
It was a phase 1 trial, part of the wider programme of RAD-140 studies. The dose rose through 50 mg, 100 mg and 150 mg once daily. The patients, whose number the table below gives, were postmenopausal women with heavily pretreated metastatic breast cancer, which had spread to distant organs, of the oestrogen-receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) kind.
The events the trial did record most often, set out in the table below, were rises in two liver enzymes, aspartate aminotransferase (AST) and its companion alanine aminotransferase (ALT), with raised AST the most frequent of all. Both leak into the blood from injured liver cells, called hepatocytes, which is why they serve as the markers of RAD-140 liver injury. A smaller share of patients had raised total bilirubin, and the same share had vomiting, dehydration, decreased appetite and decreased weight. Most patients had Grade 3/4 adverse events (severe or life-threatening), and slightly more had treatment-related adverse events, those the trial judged attributable to RAD140.
Two cautions go with these figures. They come from women with advanced, heavily pretreated cancer, in a trial with no men and no healthy volunteers, so they do not transfer directly to groups that differ in age, sex, hormonal state or health. And a list of frequent events cannot prove an absence: an effect left off the list may have fallen below the summary’s threshold for frequent events, or it may never have been recorded at all.
Will RAD140 make you tired?
Marked tiredness is not, as a rule, counted among the effects of RAD140. Fatigue did not stand out in the trial, whose record centred on the liver enzymes AST and ALT, vomiting, dehydration, decreased appetite and decreased weight. Where tiredness is linked with the compound, the link is usually indirect.
The first indirect route is RAD140 testosterone suppression: SARMs are widely understood to lower endogenous testosterone, and a low level of the body’s own hormone goes with fatigue. Dehydration, decreased appetite and possible drug-induced liver injury are the other routes usually named. All of this rests on one small, early-stage trial in participants with advanced illness, so how RAD140 affects energy after exposure remains poorly characterised.
Most frequent (> 10%) treatment-emergent adverse events (TEAEs) were elevated AST (59.1%), ALT (45.5%), and total blood bilirubin (27.3%), and vomiting, dehydration, and decreased appetite and weight (27.3% each).
Does RAD140 cause insomnia (“radsomnia”), and how common is it?
Outside the published trials, poor sleep is the effect most often linked with RAD140, so often that it has a nickname, ‘radsomnia’, on RAD-140 Reddit and elsewhere online. Insomnia, poor sleep despite adequate opportunity to rest, is not an established effect of the compound, because the trial lists no such disturbance among its common adverse events. The accounts themselves disagree, some calling radsomnia a myth, others a real change in the night’s rest. A change of that kind is at least plausible: androgens act on the central nervous system and on sleep, and RAD140 acts strongly on the androgen receptor.
In those accounts the sleep changes run from mild to severe:
mild broken sleep, with random waking and an easy return to sleep, at the lighter end;
difficulty falling asleep, further along, most often in the first weeks of exposure;
nights that were almost wholly sleepless;
heat at bedtime, in a single detailed account, with a rise in body temperature, hot and restless feet and a headache before sleep;
the opposite outcome, rarely, with sleep better than before exposure;
a lasting change, in one account, with sleep that never returned to its earlier pattern after exposure ended.
Why does RAD140 make you wake up a few hours after falling asleep?
Outside the trials, RAD140 is commonly named as a cause of waking a few hours after falling asleep, and the explanation offered is its action on the androgen receptor, which is present in the brain regions that govern arousal and the sleep-wake cycle. Sleep research calls this pattern sleep-maintenance insomnia: falling asleep is normal, but the later waking is alert and does not settle. The accounts liken it to the clear-headed wakefulness that follows coffee late in the evening.
The same accounts name other causes of the same waking:
caffeine late in the day;
nicotine late in the day;
stress over the compound’s effects;
irregular sleep times.
Each of these produces the same pattern on its own, so none of them can be separated cleanly from the compound. Accounts outside the published studies describe the waking as easing after the first weeks of exposure, but none of the explanations is established and the easing is unconfirmed.
What helps with insomnia on RAD140?
No measure is established as easing the insomnia linked with RAD140, and what is suggested comes from general sleep research, not from studies of the compound. The literature on selective androgen receptor modulators usually puts the disturbance down to stimulation of the androgen receptor, and a second, less tested explanation ties it to the fall in endogenous testosterone that follows exposure. Beyond the trial data, melatonin is named as one measure, with mixed effect.
Outside the published trials, the other measures are smaller amounts of caffeine and nicotine later in the day and regular bedtimes, and alcohol before sleep is mentioned only once. A lower level of exposure, or its end, is also described as followed by a return of sleep, which fits the view most often held, that the disturbance depends on the dose and fades once the compound is withdrawn. Research on androgen deprivation complicates that view: falling androgen levels go with poorer sleep, so the weeks after withdrawal are not necessarily free of it.
Do SARMs like RAD140 cause anxiety?
SARMs such as RAD140 are not, as a rule, held to cause anxiety directly, and the controlled research on RAD140 is too limited to show a link either way. Outside the published trials, anxiety is described as following disturbed sleep or worry about adverse effects, and in one account the worry itself fed the anxiety. In those descriptions the symptoms after exposure to SARMs and to RAD140 are these:
anxiety, less common than disturbed sleep;
restlessness, less common than disturbed sleep;
a feeling of being on edge, less common than disturbed sleep;
impaired concentration, alongside the anxiety;
a sense of unease, alongside the anxiety.
Those accounts fit the indirect causes usually proposed for the link between SARMs and mood. The first is the fall in endogenous testosterone, which goes with low mood, anxiety and impaired concentration. The second is disturbed sleep. It heightens anxiety and blunts concentration, and worry about adverse effects adds to both. The explanation rests on general androgen physiology and on accounts given after exposure, so a direct effect of RAD140 on anxiety has been neither demonstrated nor ruled out.
Is RAD140 linked to aggression or low mood?
RAD140 is generally held to have a possible but poorly established link with irritability and low mood, and beyond the trial data RAD 140 aggression rests on accounts, not on controlled measurement. The usual explanation is the connection widely drawn between androgen receptor activity and mood. A second route runs through hormones: RAD140 is understood to suppress the hypothalamic-pituitary-testicular axis that drives the testes to make testosterone, and so to lower endogenous testosterone and, with it, oestrogen.
Outside the published trials, low androgen and oestrogen levels of that kind are commonly associated with low mood, tiredness and emotional instability, both during exposure and while the body’s own hormone production recovers afterwards. The reasoning comes from general hormone physiology, not from RAD140 itself, so whether the compound causes aggression or low mood, and how often, remains unestablished.
[Figure 1. A doctor on reported RAD140 effects. A physician weighs what people report on RAD140 against what is actually known.]
Is RAD140 linked to night sweats or ringing in the ears?
Neither night sweats nor the ringing in the ears called tinnitus has an established link with RAD140. Published research on the compound centres on the suppression of endogenous testosterone, drug-induced liver injury and isolated case reports of cardiovascular events. Among the effects described outside the trials, night sweats sometimes appear as part of a wider disturbance of sleep and body-temperature regulation, and tinnitus appears in a single account.
Outside the published trials, those night sweats are usually put down to broad hormonal disruption rather than to a property of RAD140 itself. Two further facts keep the question open: the compound has never completed formal clinical safety evaluation, and material sold as research compounds is often mislabelled or contaminated. The absence of a documented link is therefore commonly treated as a gap in the evidence, not as proof that no such effect exists.
Dose and length of exposure in the trial
The RAD140 doses administered orally in the human trial were 50 mg, 100 mg and 150 mg once daily, and 100 mg a day, not 150 mg, became the maximum tolerated dose, the highest dose whose toxicity the protocol accepted. The levels came from a 3 + 3 dose-escalation design, in which three new patients enter a higher level only after the one below has shown acceptable toxicity.
Dose levels included 50 mg (n = 6), 100 mg (n = 13), and 150 mg (n = 3) once daily (QD).
The elimination half-life of RAD 140 was 44.7 hours. That is long enough to support once-daily dosing, and it means that less than half of each dose has cleared before the next arrives. What the summary does not give is any link between dose and outcome: adverse events are pooled across all patients rather than reported by dose level, and the time each patient spent on treatment is not stated. Tiredness, mood or sleep changes or any other event therefore cannot be tied to dose or to length of exposure.
What regulators found in products sold as SARMs
Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products and found them significantly under-dosed. That finding reaches into every account that ties a change in sleep or mood to a product: the change may come neither from the compound on the label nor from the amount it states, which is why telling legit RAD 140 from fakes and under-dosed material matters. It bears hardest on accounts that tie an effect to an amount, such as sleep disturbance easing at a lower level of exposure, because the amount actually present was unknown. Mood and sleep also move with caffeine, stress and bedtime habits, so the compound’s own effect cannot be separated from the rest while a product’s content is unverified.
That gap between label and content is the reason the RAD-140 for sale in our shop, like the rest of our UK SARMs, is supplied for laboratory research only, with batch and purity data for each lot, so that a researcher knows what the material contains.
What does RAD140 do to the brain?
In rat studies RAD140 protected neurons. That RAD-140 neuroprotection matched testosterone at reducing cell death in cultured neurons from the hippocampus, the brain region central to memory formation. The cultures had been exposed to triggers of apoptosis (programmed cell death), and the SARM RAD140 shielded them through mitogen-activated protein kinase (MAPK) signalling, a cascade of enzymes that relays signals to the nucleus. Two findings tied the protection to that pathway: RAD140 raised the phosphorylation of extracellular signal-regulated kinase (ERK) and the MAPK kinase inhibitor U0126 blocked the protection.
The same protection appeared in living animals. In adult male rats after gonadectomy (removal of the testes), RAD140 switched on androgenic gene regulation in the brain and protected hippocampal neurons against kainate, an excitotoxin, while largely sparing the prostate. The authors present this as initial preclinical evidence relevant to Alzheimer’s disease and related neurodegenerative diseases. It is evidence about neuronal survival in animals and cultured cells, not about mood, anxiety or sleep, so it says nothing about how RAD140 acts on those functions in humans.
[Figure 2. RAD140 neuroprotection through MAPK–ERK in rat cells. In cultured rat hippocampal neurons, RAD140 raised phosphorylated ERK, a survival signal of the MAPK cascade, and reduced cell death after apoptotic triggers; the pathway blocker U0126 removed that protection. The outcome is neuron survival in rat cells, not mood, sleep or a human brain.]
Limits of the evidence on RAD140, mood and sleep
Each tier of the evidence stops short in its own way. The human tier is one small trial in women with advanced, heavily pretreated cancer, so any effect outside its list of frequent events is uncharacterised. The brain tier is rats and cultured neurons exposed to RAD140, and it measured cell survival rather than behaviour. The descriptions outside the trials are self-selected and cannot give a rate, and the regulator’s testing showed that the products behind them may not match their labels. Taken together these tiers leave the human evidence on RAD 140 lethargy, mood and sleep resting on a trial never designed to capture them and on accounts that cannot be traced to a compound of verified content.
Descriptions outside the trials are the only record of insomnia, sleep-maintenance insomnia, anxiety, irritability and anger, low mood, tiredness, night sweats, tinnitus and restless legs, and no published study among this article’s sources has measured any of these effects.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In RAD140's only human trial, which adverse event was recorded most often?
Raised AST, a liver enzyme ✓
Insomnia and broken sleep
Tiredness and low energy
Anxiety and restless nights
Raised AST led the trial's list at 59.1%, and no tiredness, mood or sleep change appeared among its most frequent events.
Why does the trial's silence on sleep and mood leave the question open?
It enrolled only young, healthy male volunteers
It ran too briefly for any effect to show
It was small and used no mood or sleep scale ✓
It measured sleep but never published the scores
The trial studied safety and antitumour activity in 22 women with advanced cancer and named no mood or sleep scale, so rarer effects could fall below its threshold or go unrecorded.
What did the rat brain studies of RAD140 actually measure?
Sleep patterns in treated rats
Survival of neurons after injury ✓
Aggression between caged males
Anxiety-like behaviour in maze tests
In cultured neurons and kainate-lesioned rats, RAD140 matched testosterone at reducing neuron death, and the studies did not measure behaviour, mood or sleep.
What did Australia's TGA find when it tested unapproved SARM products?
Contents that matched their labels
More compound than labelled
Unlisted stimulants such as caffeine
Far less compound than labelled ✓
The TGA found unapproved SARM products well below their stated strength, so effects described online cannot be tied to a known amount of compound.
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.
Hurry while stocks last! Use code PAYDAY15 at checkout to get 15% off sitewide. Valid for
Join the WaitlistWe will inform you when the product is back in stock. Enter your email address below.
RAD 140 lethargy: mood, sleep and what the evidence shows
By Elizabeth Hyams · Reviewed by Laura Walker, PhD
Published · Updated · 16 min read
RAD140, lethargy, mood and sleep in brief
Controlled research has not shown RAD 140 lethargy, and the same goes for aggression, anxiety and insomnia, poor sleep despite enough opportunity to rest. The only human trial of RAD140 enrolled 22 women with advanced breast cancer, too few to rule such effects out. None appeared among its most frequent adverse events: raised liver enzymes, vomiting, dehydration and decreased appetite.
What is said about tiredness, mood and sleep comes mostly from accounts outside the trials, and there disturbed sleep is the complaint most often tied to RAD140, with anxiety, anger and tiredness mentioned less often. The rat studies do not fill the gap, because they measured whether neurons survived, not how the animals slept or behaved. So the trial is the only measured human record, and the RAD 140 mental effects this article follows, aggression, anxiety, disturbed sleep and tiredness, sit largely outside it.
Mood, sleep and energy effects against the evidence
Why would a compound tested against breast cancer touch sleep or mood at all? Testolone, as RAD140 is also called, is a selective androgen receptor modulator (SARM): it binds the androgen receptor, the protein inside cells through which testosterone and the other androgens act. Those hormones act on the brain as well as on muscle. That binding is the whole of the RAD 140 mechanism of action. The compound is orally active and reached clinical trials under the name vosilasarm.
Sleep, mood and energy are one strand of the wider record of RAD 140 side effects, which also covers liver injury, effects on the heart and changes in libido, and those strands belong to the parent article. Here the question is narrower: what the one human trial recorded about tiredness, mood and sleep, what is described outside it, and what the rat brain studies can and cannot add.
Mood, sleep and energy in the first human trial
The one human trial of RAD140 did not list tiredness, a change in mood or disturbed sleep among its most frequent treatment-emergent adverse events, the unwanted effects that begin or worsen once treatment starts. That silence has a plain cause. The trial was built to measure safety, tolerability, dosing, pharmacokinetics and activity against the tumour, and its published summary names no scale for mood or sleep. A complaint of tiredness could reach the record only if a patient reported it during treatment; nothing was scored against a baseline.
It was a phase 1 trial, part of the wider programme of RAD-140 studies. The dose rose through 50 mg, 100 mg and 150 mg once daily. The patients, whose number the table below gives, were postmenopausal women with heavily pretreated metastatic breast cancer, which had spread to distant organs, of the oestrogen-receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) kind.
The events the trial did record most often, set out in the table below, were rises in two liver enzymes, aspartate aminotransferase (AST) and its companion alanine aminotransferase (ALT), with raised AST the most frequent of all. Both leak into the blood from injured liver cells, called hepatocytes, which is why they serve as the markers of RAD-140 liver injury. A smaller share of patients had raised total bilirubin, and the same share had vomiting, dehydration, decreased appetite and decreased weight. Most patients had Grade 3/4 adverse events (severe or life-threatening), and slightly more had treatment-related adverse events, those the trial judged attributable to RAD140.
Adverse events in the phase 1 trial
Two cautions go with these figures. They come from women with advanced, heavily pretreated cancer, in a trial with no men and no healthy volunteers, so they do not transfer directly to groups that differ in age, sex, hormonal state or health. And a list of frequent events cannot prove an absence: an effect left off the list may have fallen below the summary’s threshold for frequent events, or it may never have been recorded at all.
Will RAD140 make you tired?
Marked tiredness is not, as a rule, counted among the effects of RAD140. Fatigue did not stand out in the trial, whose record centred on the liver enzymes AST and ALT, vomiting, dehydration, decreased appetite and decreased weight. Where tiredness is linked with the compound, the link is usually indirect.
The first indirect route is RAD140 testosterone suppression: SARMs are widely understood to lower endogenous testosterone, and a low level of the body’s own hormone goes with fatigue. Dehydration, decreased appetite and possible drug-induced liver injury are the other routes usually named. All of this rests on one small, early-stage trial in participants with advanced illness, so how RAD140 affects energy after exposure remains poorly characterised.
Does RAD140 cause insomnia (“radsomnia”), and how common is it?
Outside the published trials, poor sleep is the effect most often linked with RAD140, so often that it has a nickname, ‘radsomnia’, on RAD-140 Reddit and elsewhere online. Insomnia, poor sleep despite adequate opportunity to rest, is not an established effect of the compound, because the trial lists no such disturbance among its common adverse events. The accounts themselves disagree, some calling radsomnia a myth, others a real change in the night’s rest. A change of that kind is at least plausible: androgens act on the central nervous system and on sleep, and RAD140 acts strongly on the androgen receptor.
In those accounts the sleep changes run from mild to severe:
Why does RAD140 make you wake up a few hours after falling asleep?
Outside the trials, RAD140 is commonly named as a cause of waking a few hours after falling asleep, and the explanation offered is its action on the androgen receptor, which is present in the brain regions that govern arousal and the sleep-wake cycle. Sleep research calls this pattern sleep-maintenance insomnia: falling asleep is normal, but the later waking is alert and does not settle. The accounts liken it to the clear-headed wakefulness that follows coffee late in the evening.
The same accounts name other causes of the same waking:
Each of these produces the same pattern on its own, so none of them can be separated cleanly from the compound. Accounts outside the published studies describe the waking as easing after the first weeks of exposure, but none of the explanations is established and the easing is unconfirmed.
What helps with insomnia on RAD140?
No measure is established as easing the insomnia linked with RAD140, and what is suggested comes from general sleep research, not from studies of the compound. The literature on selective androgen receptor modulators usually puts the disturbance down to stimulation of the androgen receptor, and a second, less tested explanation ties it to the fall in endogenous testosterone that follows exposure. Beyond the trial data, melatonin is named as one measure, with mixed effect.
Outside the published trials, the other measures are smaller amounts of caffeine and nicotine later in the day and regular bedtimes, and alcohol before sleep is mentioned only once. A lower level of exposure, or its end, is also described as followed by a return of sleep, which fits the view most often held, that the disturbance depends on the dose and fades once the compound is withdrawn. Research on androgen deprivation complicates that view: falling androgen levels go with poorer sleep, so the weeks after withdrawal are not necessarily free of it.
Do SARMs like RAD140 cause anxiety?
SARMs such as RAD140 are not, as a rule, held to cause anxiety directly, and the controlled research on RAD140 is too limited to show a link either way. Outside the published trials, anxiety is described as following disturbed sleep or worry about adverse effects, and in one account the worry itself fed the anxiety. In those descriptions the symptoms after exposure to SARMs and to RAD140 are these:
Those accounts fit the indirect causes usually proposed for the link between SARMs and mood. The first is the fall in endogenous testosterone, which goes with low mood, anxiety and impaired concentration. The second is disturbed sleep. It heightens anxiety and blunts concentration, and worry about adverse effects adds to both. The explanation rests on general androgen physiology and on accounts given after exposure, so a direct effect of RAD140 on anxiety has been neither demonstrated nor ruled out.
Is RAD140 linked to aggression or low mood?
RAD140 is generally held to have a possible but poorly established link with irritability and low mood, and beyond the trial data RAD 140 aggression rests on accounts, not on controlled measurement. The usual explanation is the connection widely drawn between androgen receptor activity and mood. A second route runs through hormones: RAD140 is understood to suppress the hypothalamic-pituitary-testicular axis that drives the testes to make testosterone, and so to lower endogenous testosterone and, with it, oestrogen.
Outside the published trials, low androgen and oestrogen levels of that kind are commonly associated with low mood, tiredness and emotional instability, both during exposure and while the body’s own hormone production recovers afterwards. The reasoning comes from general hormone physiology, not from RAD140 itself, so whether the compound causes aggression or low mood, and how often, remains unestablished.
Is RAD140 linked to night sweats or ringing in the ears?
Neither night sweats nor the ringing in the ears called tinnitus has an established link with RAD140. Published research on the compound centres on the suppression of endogenous testosterone, drug-induced liver injury and isolated case reports of cardiovascular events. Among the effects described outside the trials, night sweats sometimes appear as part of a wider disturbance of sleep and body-temperature regulation, and tinnitus appears in a single account.
Outside the published trials, those night sweats are usually put down to broad hormonal disruption rather than to a property of RAD140 itself. Two further facts keep the question open: the compound has never completed formal clinical safety evaluation, and material sold as research compounds is often mislabelled or contaminated. The absence of a documented link is therefore commonly treated as a gap in the evidence, not as proof that no such effect exists.
Dose and length of exposure in the trial
The RAD140 doses administered orally in the human trial were 50 mg, 100 mg and 150 mg once daily, and 100 mg a day, not 150 mg, became the maximum tolerated dose, the highest dose whose toxicity the protocol accepted. The levels came from a 3 + 3 dose-escalation design, in which three new patients enter a higher level only after the one below has shown acceptable toxicity.
The elimination half-life of RAD 140 was 44.7 hours. That is long enough to support once-daily dosing, and it means that less than half of each dose has cleared before the next arrives. What the summary does not give is any link between dose and outcome: adverse events are pooled across all patients rather than reported by dose level, and the time each patient spent on treatment is not stated. Tiredness, mood or sleep changes or any other event therefore cannot be tied to dose or to length of exposure.
What regulators found in products sold as SARMs
Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products and found them significantly under-dosed. That finding reaches into every account that ties a change in sleep or mood to a product: the change may come neither from the compound on the label nor from the amount it states, which is why telling legit RAD 140 from fakes and under-dosed material matters. It bears hardest on accounts that tie an effect to an amount, such as sleep disturbance easing at a lower level of exposure, because the amount actually present was unknown. Mood and sleep also move with caffeine, stress and bedtime habits, so the compound’s own effect cannot be separated from the rest while a product’s content is unverified.
That gap between label and content is the reason the RAD-140 for sale in our shop, like the rest of our UK SARMs, is supplied for laboratory research only, with batch and purity data for each lot, so that a researcher knows what the material contains.
What does RAD140 do to the brain?
In rat studies RAD140 protected neurons. That RAD-140 neuroprotection matched testosterone at reducing cell death in cultured neurons from the hippocampus, the brain region central to memory formation. The cultures had been exposed to triggers of apoptosis (programmed cell death), and the SARM RAD140 shielded them through mitogen-activated protein kinase (MAPK) signalling, a cascade of enzymes that relays signals to the nucleus. Two findings tied the protection to that pathway: RAD140 raised the phosphorylation of extracellular signal-regulated kinase (ERK) and the MAPK kinase inhibitor U0126 blocked the protection.
The same protection appeared in living animals. In adult male rats after gonadectomy (removal of the testes), RAD140 switched on androgenic gene regulation in the brain and protected hippocampal neurons against kainate, an excitotoxin, while largely sparing the prostate. The authors present this as initial preclinical evidence relevant to Alzheimer’s disease and related neurodegenerative diseases. It is evidence about neuronal survival in animals and cultured cells, not about mood, anxiety or sleep, so it says nothing about how RAD140 acts on those functions in humans.
Limits of the evidence on RAD140, mood and sleep
Each tier of the evidence stops short in its own way. The human tier is one small trial in women with advanced, heavily pretreated cancer, so any effect outside its list of frequent events is uncharacterised. The brain tier is rats and cultured neurons exposed to RAD140, and it measured cell survival rather than behaviour. The descriptions outside the trials are self-selected and cannot give a rate, and the regulator’s testing showed that the products behind them may not match their labels. Taken together these tiers leave the human evidence on RAD 140 lethargy, mood and sleep resting on a trial never designed to capture them and on accounts that cannot be traced to a compound of verified content.
Descriptions outside the trials are the only record of insomnia, sleep-maintenance insomnia, anxiety, irritability and anger, low mood, tiredness, night sweats, tinnitus and restless legs, and no published study among this article’s sources has measured any of these effects.
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
Raised AST led the trial's list at 59.1%, and no tiredness, mood or sleep change appeared among its most frequent events.
The trial studied safety and antitumour activity in 22 women with advanced cancer and named no mood or sleep scale, so rarer effects could fall below its threshold or go unrecorded.
In cultured neurons and kainate-lesioned rats, RAD140 matched testosterone at reducing neuron death, and the studies did not measure behaviour, mood or sleep.
The TGA found unapproved SARM products well below their stated strength, so effects described online cannot be tied to a known amount of compound.
Elizabeth Hyams · Imperial College London
Specialty Registrar in Endocrinology and Diabetes; Clinical Research Fellow
Elizabeth Hyams is a specialty registrar in endocrinology and diabetes and a clinical research fellow in the Reproductive Endocrinology group at Imperial College London. Elizabeth specialises in endocrinology and the hypothalamic-pituitary-gonadal axis.
Laura Walker, PhD · Newcastle University · Last reviewed
Postdoctoral Research Associate
Laura Walker is a postdoctoral research associate at the Translational and Clinical Research Institute, Newcastle University. Laura specialises in androgen receptor pharmacology.
Related Posts
RAD 140 side effects: what the trials and case reports show
Raised liver function tests were the commonest RAD 140 side effects in the only full human trial; case reports add liver injury and heart inflammation.
Is MK-677 liver toxic? The liver and kidney evidence
Is MK-677 liver toxic: trials found it well tolerated, but a case report links it alone to raised liver enzymes that settled once exposure ended.
How bad is RAD-140 for the heart? What the evidence shows
How bad is RAD-140 for the heart remains unmeasured in published studies, while case reports describe myocarditis and heart failure after exposure.
Is RAD140 liver toxic? What trials and case reports show
Is RAD140 liver toxic: raised liver enzymes were the most frequent adverse event in its only human trial, and case reports describe cholestatic jaundice.